An international shortage of Intravesical Bacillus Calmette-Guérin (BCG) therapy has considerably affected clinical practice patterns for non-muscle invasive bladder cancer. We aimed to review the trends of BCG therapy in Australia between April 2006 and 2016 using Pharmaceutical Benefits Australia data. A sudden, global drop in October/November 2014 and a precipitous fall for the CIS indication in June/July 2012 was identified. After restoration of supply, BCG prescriptions for primary and relapsing TCC rebounded to a higher level than prior to the first shock. For carcinoma in-situ (CIS) the number of prescriptions did not rebound and are currently close to zero. This article is protected by copyright. All rights reserved.
BJU international. 2017 Oct 26 [Epub ahead of print]
Marlon Perera, Nathan Papa, Daniel Christidis, Shannon McGrath, Todd Manning, Matthew Roberts, Damien Bolton, Nathan Lawrentschuk, Shomik Sengupta
Department of Surgery, Austin Health, The University of Melbourne, Victoria, Australia., Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.